Approach to the patient with extremely low HDL-cholesterol.

Patients with extremely low high-density lipoprotein-cholesterol (HDL-C) pose distinct challenges to clinical diagnosis and management. Confirmation of HDL-C levels below 20 mg/dl in the absence of severe hypertriglyceridemia should be followed by evaluation for secondary causes, such as androgen use, malignancy, and primary monogenic disorders, namely, apolipoprotein A-I mutations, Tangier disease, and lecithin-cholesterol acyltransferase deficiency. Global cardiovascular risk assessment is a critical component of comprehensive evaluation, although the association between extremely low HDL-C levels and atherosclerosis remains unclear. Therapeutic interventions address reversible causes of low HDL-C, multiorgan abnormalities that may accompany primary disorders and cardiovascular risk modification when appropriate. Uncommon encounters with patients exhibiting extremely low HDL-C provide an opportunity to directly observe the role of HDL metabolism in atherosclerosis and beyond the vascular system.

[1]  T. Dawber,et al.  The Framingham Study , 2014 .

[2]  G. Franceschini,et al.  Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. , 2012, Atherosclerosis.

[3]  G. Franceschini,et al.  Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma. , 2012, Archives of internal medicine.

[4]  D. Rader,et al.  Pharmacologic Suppression of Hepatic ATP-Binding Cassette Transporter 1 Activity in Mice Reduces High-Density Lipoprotein Cholesterol Levels but Promotes Reverse Cholesterol Transport , 2011, Circulation.

[5]  D. Rader,et al.  Novel HDL-directed pharmacotherapeutic strategies , 2011, Nature Reviews Cardiology.

[6]  T. Leren,et al.  Lecithin:Cholesterol Acyltransferase (LCAT) Deficiency: Renal Lesions with Early Graft Recurrence , 2011, Ultrastructural pathology.

[7]  T. Klupa,et al.  Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency , 2011, Clinical and Experimental Nephrology.

[8]  Elizabeth M. Hosfield,et al.  Disseminated Intravascular Large B Cell Lymphoma with Slowly Decreasing High-Density Lipoprotein Cholesterol , 2011, Southern medical journal.

[9]  E. Schaefer,et al.  Marked HDL deficiency and premature coronary heart disease , 2010, Current opinion in lipidology.

[10]  M. Hayden,et al.  Targeted Deletion of Hepatocyte ABCA1 Leads to Very Low Density Lipoprotein Triglyceride Overproduction and Low Density Lipoprotein Hypercatabolism* , 2010, The Journal of Biological Chemistry.

[11]  R. Frikke-Schmidt.  Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. , 2010, Atherosclerosis.

[12]  G. Franceschini,et al.  Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans , 2009, Circulation.

[13]  D. Mymin,et al.  Iatrogenic Severe Depression of High‐Density Lipoprotein Cholesterol , 2009, Journal of clinical pharmacology.

[14]  T. Sampietro,et al.  Images in cardiovascular medicine. Tangier disease in severely progressive coronary and peripheral artery disease. , 2009, Circulation.

[15]  A. Remaley,et al.  Lecithin: cholesterol acyltransferase--from biochemistry to role in cardiovascular disease. , 2009, Current opinion in endocrinology, diabetes, and obesity.

[16]  Børge G Nordestgaard,et al.  Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[17]  C. Shapira,et al.  High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate , 2007, Pharmacoepidemiology and drug safety.

[18]  E. Bruckert.  Epidemiology of low HDL-cholesterol: results of studies and surveys , 2006 .

[19]  R. Goldberg.  Impact of thiazolidenediones on serum lipoprotein levels , 2006, Current atherosclerosis reports.

[20]  M. Langlois,et al.  Historical milestones in measurement of HDL-cholesterol: impact on clinical and laboratory practice. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[21]  A. Eckardstein.  Differential diagnosis of familial high density lipoprotein deficiency syndromes. , 2006 .

[22]  L. Tsai,et al.  Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[23]  Jonathan C. Cohen,et al.  Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol , 2004, Science.

[24]  D. Capuzzi,et al.  Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione. , 2003, Annals of internal medicine.

[25]  G. Franceschini,et al.  Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency. , 2003, Atherosclerosis.

[26]  Y. Nakaya,et al.  Alterations in erythrocyte membrane lipid and its fragility in a patient with familial lecithin:cholesterol acyltrasferase (LCAT) deficiency. , 2002, The journal of medical investigation : JMI.

[27]  M. Yumoto,et al.  Apolipoprotein A-I deficiency with accumulated risk for CHD but no symptoms of CHD. , 2002, Atherosclerosis.

[28]  D. Rader,et al.  ABC1: connecting yellow tonsils, neuropathy, and very low HDL. , 1999, The Journal of clinical investigation.

[29]  G. Luc,et al.  Metabolism of Apolipoproteins AI and AII in a Patient with Paradoxical Reduction in High-Density Lipoprotein Due to Ciprofibrate , 1999, Annals of clinical biochemistry.

[30]  M. Kessler,et al.  Recurrence of lecithin cholesterol acyltransferase deficiency after kidney transplantation. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[31]  KeijiroSaku,et al.  A New Case of ApoA-I Deficiency Showing Codon 8 Nonsense Mutation of the ApoA-I Gene Without Evidence of Coronary Heart Disease , 1995 .

[32]  P. Wilson,et al.  Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. , 1994, Journal of lipid research.

[33]  B. Laurent,et al.  Pathology of roots, spinal cord and brainstem in syringomyelia-like syndrome of Tangier disease , 1991, Journal of the Neurological Sciences.

[34]  G. Glazer,et al.  Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. , 1991, Archives of internal medicine.

[35]  R. Mahley,et al.  DECREASED HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH SIGNIFICANT LIPOPROTEIN MODIFICATIONS AND WITHOUT CLINICAL ATHEROSCLEROSIS IN AN ITALIAN FAMILY , 1980 .

[36]  L. Carlson.  A FURTHER CASE OF FISH-EYE DISEASE , 1979, The Lancet.

[37]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[38]  K. Norum,et al.  Familial serum-cholesterol esterification failure. A new inborn error of metabolism. , 1967, Biochimica et biophysica acta.

[39]  Lawrence A Leiter,et al.  Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. , 1994, The Journal of clinical investigation.

[40]  W. H. Heaton,et al.  Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. , 1982, Arteriosclerosis.